bpi glp-1 🚨 FDA Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of medications like semaglutide and tirzepatide, signaling a major shift in how these GLP-ONE + Receptor Activator

This is a clinical tool

Semaglutide is a medication that helps with the pancreas production of insulin

Current Status of Compounding of Semaglutide: With respect to the current status of compounding of semaglutide, FDA noted that it wished to avoid unnecessary disruption to patient treatment, and outlined the current enforcement policy moving forward: [T]he agency does not intend to take action against compounders for violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) arising from conditions that depend on semaglutide injection products inclusion on FDAs drug shortage list: For a state-licensed pharmacy under section 503A of the FD&C Act compounding, distributing or dispensing semaglutide injections within 60 calendar days from todays announcement, until

Zepbound vials offer significant cost-savings compared to the pen

This peptide, which they named 'exendin-4', not only stimulated insulin secretion in the same way as GLP-1 but also had the advantage that it remained active for more than two hours after subcutaneous injection